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Original ArticleAdipose specific disruption of seipin causes
early-onset generalised lipodystrophy and
altered fuel utilisation without severe metabolic
diseaseGeorge D. Mcilroy 1, Karla Suchacki 2, Anke J. Roelofs 3, Wulin Yang 4, Yanyun Fu 5, Bo Bai 5,
Robert J. Wallace 6, Cosimo De Bari 3, William P. Cawthorn 2, Weiping Han 5, Mirela Delibegovic 3,
Justin J. Rochford 1,*ABSTRACT
Objective: Mutations to the BSCL2 gene disrupt the protein seipin and cause the most severe form of congenital generalised lipodystrophy (CGL).
Affected individuals exhibit a near complete loss of white adipose tissue (WAT) and suffer from metabolic disease. Seipin is critical for adipocyte
development in culture and mice with germline disruption to Bscl2 recapitulate the effects of BSCL2 disruption in humans. Here we examined
whether loss of Bscl2 specifically in developing adipocytes in vivo is sufficient to prevent adipose tissue development and cause all features
observed with congenital BSCL2 disruption.
Methods: We generated and characterised a novel mouse model of Bscl2 deficiency in developing adipocytes (Ad-B2(/)) using the adipose-
specific Adiponectin-Cre line.
Results: We demonstrate that Ad-B2(/) mice display early onset lipodystrophy, in common with congenital Bscl2 null mice and CGL2 patients.
However, glucose intolerance, insulin resistance, and severe hepatic steatosis are not apparent. Food intake and energy expenditure are un-
changed, but Ad-B2(/) mice exhibit significantly altered substrate utilisation. We also find differential effects of seipin loss between specific
adipose depots revealing new insights regarding their varied characteristics. When fed a high-fat diet, Ad-B2(/) mice entirely fail to expand
adipose mass but remain glucose tolerant.
Conclusions: Our findings demonstrate that disruption of Bscl2 specifically in developing adipocytes is sufficient to cause the early-onset
generalised lipodystrophy observed in patients with mutations in BSCL2. However, this significant reduction in adipose mass does not cause
the overt metabolic dysfunction seen in Bscl2 knockout mice, even following a high-fat diet challenge.
 2018 The Authors. Published by Elsevier GmbH. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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Congenital generalised lipodystrophy (CGL) is a rare, autosomal
recessive, genetic disorder characterised by dramatically reduced
adipose tissue mass from birth [1]. Individuals with CGL develop he-
patic steatosis, hyperlipidaemia, and severe insulin resistance. This is
predicted to result from the inability to increase the number of new
adipocytes by adipogenesis and/or expand existing adipose cells to
safely store dietary nutrients, principally as triglyceride. So far, mu-
tations in four genes have been identified that cause CGL: AGPAT2
(CGL type 1) [2], BSCL2 (CGL type 2) [3], CAV1 (CGL type 3) [4], and
PTRF (CGL type 4) [5]. A mutation in the promoter of the FOS gene is
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CGL of known genetic cause. Patients with homozygous or compound
heterozygous loss of function mutations in BSCL2 exhibit the most
severe form, CGL2 [7]. Affected individuals almost entirely lack both
metabolic and mechanical adipose tissue depots and typically suffer
from severe insulin resistance, dyslipidemia, hepatic steatosis, and
hyperphagia due to extremely low circulating levels of the satiety
hormone leptin [8]. BSCL2 is highly expressed in adipose tissue;
however, it is also expressed in other tissues with the highest
expression levels being found in the testes and brain [3,9]. BSCL2
encodes the protein seipin, an endoplasmic reticulum (ER) trans-
membrane protein capable of forming homo-oligomers that may act as
molecular scaffolds and/or directly modulate lipid droplet dynamicsarch Institute, University of Edinburgh, Edinburgh, UK 3Institute of Medical Sciences,
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Original Article[10,11]. Cellular studies have revealed that knockdown of Bscl2 im-
pairs adipogenesis and provided the first mechanistic insights to the
cause of CGL2 [12,13]. Seipin has been reported to interact with
multiple proteins via which it may influence adipogenesis, including
regulators of triacylglycerol/glycerophospholipid synthesis (LIPIN1,
AGPAT2 and GPAT3) [14e16], ER calcium signalling (SERCA) [17] and
cytoskeletal organisation [18]. Despite these advances, the exact
molecular function of seipin remains uncertain. Three independent
laboratories have generated mouse models with germline disruption to
Bscl2 [19e21]. All models developed severe lipodystrophy, confirming
the requirement of seipin for adipose tissue development and/or
maintenance. Bscl2 null mice exhibit insulin resistance and almost all
other phenotypic characteristics of CGL2 patients, with the exception of
hypertriglyceridemia [7], although this is also observed with Bscl2 null
mice also lacking the low density lipoprotein receptor [22]. Re-
expression of seipin in adipocytes under the control of the aP2 pro-
moter in Bscl2 null mice rescues lipodystrophy, insulin resistance and
hepatic steatosis [23]. However, this does not specifically demonstrate
that the loss of seipin only in developing adipose tissue can drive the
full CGL phenotype. Moreover, the analysis is complicated by the
known capacity of the aP2 promoter to drive expression in non-adipose
tissues [24,25]. The aP2-Cre model has also been used to selectively
ablate Bscl2 in adipocytes but, unlike congenital seipin loss in mice
and humans, this does not significantly alter adipose mass in early life
and instead leads to a progressive loss of adipose tissue in adulthood
[26]. A tamoxifen-inducible Adipoq-CreER model has been used to
examine the effects of acute loss of seipin in mature adipocytes in
adult mice, revealing valuable insights regarding the importance of
seipin for adipocyte maintenance and function [27]. However,
tamoxifen itself can influence adipose development and function and
therefore can confound interpretation when used in such studies [28].
In this study, we have used the non-inducible Adipoq-Cre model to
investigate the consequences of ablating Bscl2 in developing and
mature adipocytes. This strategy has been shown to efficiently target
developing adipocytes in other in vivo studies of key adipogenic genes
[29,30]. Our data reveal that seipin deficiency in developing adipocytes
is sufficient to cause severe generalised lipodystrophy early in life but
that this does not induce all of the metabolic consequences of
congenital seipin deficiency.
2. METHODS
2.1. Animal studies
Bscl2tm1a(EUCOMM)Hmgu mice were generated using ES cells sourced
from EUCOMM [31]. The LacZ/Neo cassette preceding exon 5 was
removed by Flp/Frt recombination to generate mice in which LoxP sites
were inserted either side of exons 5e7 of Bscl2 (Bscl2(fl/fl) mice). To
generate seipin knockout mice (SKO), Bscl2tm1a(EUCOMM)Hmgu mice
were crossed with oocyte-specific ZP3-Cre transgenic mice. Experi-
mental SKO mice were generated by crossing heterozygous mice and
analyses were performed with male SKO mice and male wild-type
littermates. To generate an adipocyte-specific model of seipin defi-
ciency (Ad-B2(/)), homozygous Bscl2(fl/fl) mice were crossed with
heterozygous Bscl2(fl/wt) mice also containing Cre recombinase driven
by the Adipoq promoter (Adiponectin-Cre). Adiponectin-Cre mice were
generously provided by Dr Evan Rosen, Beth Israel Deaconess Medical
Center, Harvard Medical School, Boston, USA. Animal procedures
conducted on Ad-B2(/) mice were approved by the University of
Aberdeen Ethics Review Board and performed under a project license
(PPL: P94B395EO) approved by the UK Home Office. All experiments
used male mice, which were group-housed at 20e22 C and exposed2
 2018 The Authors. Published by Elsevier Gto a 12hr/12hr lightedark period. Male littermates heterozygous
for both Adiponectin-Cre and Bscl2(fl/wt) were used as controls
(Ad-B2(þ/)). Mice were always given ad libitum access to water and a
standard rodent chow diet (CRM (P) 801722, Special Diets Services)
unless otherwise stated. Tissues were rapidly dissected post-mortem,
frozen in liquid nitrogen then stored at 70 C.
2.2. Metabolic studies
Fat and lean mass were measured in mice aged 6 and 12 weeks (chow
diet) or 8, 10, and 12 weeks of age (high-fat diet) using the
EchoMRI-500 body composition analyser (Zinsser Analytic GmbH)
then normalised to body weight. Food intake, water intake, activity,
energy expenditure (EE), and respiratory exchange ratio (RER) were
continuously measured using the PhenoMaster/LabMaster Home Cage
System (TSE Systems). Mice were individually housed and acclima-
tised for one week prior to metabolic measurements being taken. Prior
to glucose tolerance tests (GTT), mice were placed into clean cages,
and food was withheld for 5 h. Basal glucose readings (0 min) were
determined by glucometer readings (AlphaTrak II, Zoetisus) from tail
punctures. Mice were then given a 2 mg/g D-glucose (Sigma) bolus by
intraperitoneal injection. Blood glucose levels were monitored at 15,
30, 60, and 120 min. Mice had ad libitum access to water throughout.
A separate cohort of eight-week-old Ad-B2(/) and Ad-B2(þ/)
littermate controls were group-housed and placed on a high-fat diet
(60% kcals from fat (D12492), Research Diets) for four weeks. All mice
had ad libitum access to food and water unless otherwise stated.
2.3. Histology
Immediately following CO2 anaesthesia and cervical dislocation,
epididymal white adipose tissue (EWAT), subcutaneous white adipose
tissue (SWAT), and brown adipose tissue (BAT) were immersed in 10%
formalin and stored at 4 C for 24 h. Tissues were then transferred to
PBS. Tissues were processed on a Peloris Tissue Processor (Leica) and
were embedded into Sakura Tissue-Tek III paraffin wax (melting point
54e57 C). Sections were cut at 4 mm intervals and dried at 37 C
overnight. Sections were then stained with H&E. Caudal vertebrae
were fixed in formalin at 4 C for one week, washed in PBS, and then
decalcified in 14% EDTA for 14 days at 4 C. Caudal vertebrae were
paraffin wax-embedded, 6 mm sections were taken every 100 mm and
dried at 37 C overnight. Sections were stained with H&E, and the size
distribution of marrow adipocyte area was determined by manual
counting using Image J software, 300 adipocytes were counted per
animal. Knees were fixed in 4% methanol-free paraformaldehyde (PFA;
TAAB, Reading, UK) overnight, followed by decalcification in 4e10%
EDTA (WVR Chemicals, Leuven, Belgium) for 2e4 weeks at 4 C. They
were then dehydrated, embedded in paraffin, and cut into 5 mm-thick
sagittal sections. For each knee, sections were selected for analysis
using the posterior cruciate ligament as central landmark. Sections
were rehydrated, stained with H&E, and tile-scanned on a Zeiss Axi-
oscan Z1 slide scanner (Carl Zeiss Ltd). Average IFP surface area and
average number of adipocytes were determined manually from 2 to
3 H&E-stained sections per knee using ZEN2010 software (Carl Zeiss
Ltd) by an experimenter blinded to the mouse genotype.
10 mm sections of frozen livers were cut at20 C, fixed for 10 min in
formalin, rinsed in PBS, and then stained with oil red O essentially as
described in [12].
2.4. Marrow adipose tissue quantification by osmium staining and
mCT
Tibiae were isolated and, after removal of external soft tissue, fixed in
10% formalin for 2e4 days at 4 C. Fixed tibiae were decalcified inMOLECULAR METABOLISM- (2018) 1e11
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14% EDTA for 14 days and then washed in Sorensen’s Phosphate
buffer (81 mM KH2PO4, 19 mM Na2HPO4 , 7H2O, pH 7.4). Decalcified
tibiae were stored in Sorensen’s Phosphate buffer at 4 C until ready to
be stained with osmium tetroxide. To do so, osmium tetroxide solution
(2% w/v; Agar Scientific, UK) was diluted 1:1 in Sorensen’s Phosphate
buffer. Tibiae were then stained in this 1% osmium tetroxide solution
for 48 h at room temperature, washed, and stored in Sorensen’s
Phosphate buffer at 4 C. For micro computed tomography (mCT)
analysis, layers of four to five stained tibiae were arranged in parallel in
1% agarose in a 30-mL universal tube and mounted in a Skyscan 1172
desktop micro CT (Bruker, Kontich, Belgium). The samples were then
scanned through 360 using a step of 0.40 between exposures. A
voxel resolution of 12.05 mm was obtained in the scans using the
following control settings: 54 kV source voltage, 185 mA source current
with an exposure time of 885 ms. A 0.5-mm aluminium filter and two-
frame averaging were used to optimize the scan. After scanning, the
data were reconstructed using Skyscan software NRecon v1.6.9.4
(Bruker, Kontich, Belgium). The reconstruction thresholding window
was optimized to encapsulate the target image. Volumetric analysis
was performed using CT Analyser v1.13.5.1 (Bruker, Kontich,
Belgium).
2.5. Gene expression
Total RNA was extracted from frozen tissues using the RNeasy mini kit
(Qiagen) following the manufacturer’s protocol, or a standard guani-
dinium thiocyanate-phenol-chloroform extraction protocol. Equal
quantities of RNA were DNase I treated (Sigma) then reverse tran-
scribed with M-MLV reverse transcriptase, 5X reaction buffer, dNTP’s
and random primers (Promega). Real-time quantitative PCR was per-
formed on the 7900HT system (Applied Biosystems) or CFX384
Touch Real-Time PCR Detection System (BioRad). NTC and NoRT
controls were performed for every gene analysed. The geometric mean
of three stable reference genes (Nono, Ywhaz, and Hprt) was used for
normalisation.
2.6. Western blotting
Frozen BAT tissues were homogenised in RIPA lysis buffer containing
cOmplete protease inhibitor cocktail (Roche). Protein concentrations
were determined by BCA assay (Thermo). SDS-PAGE was performed
using equal quantities of protein which were transferred to PVDF
membrane using standard protocols. Antibodies used included anti-
Bscl2 (ab106793, Abcam) and anti-Calnexin (ab75801, Abcam).
Anti-Rabbit HRP secondary antibody was used (Cell Signaling) and was
visualized using enhanced chemiluminescence (ECL substrate, Illu-
minata) and quantified by densitometry scanning using Image J
software.
2.7. Serum analysis
Blood was collected from 16-week old chow fed mice fasted for 5 h by
cardiac puncture, placed and inverted in SST amber tubes (BD
Microtainer) and incubated at room temperature for 30 min. Samples
were then centrifuged at 12,000g for 10 min and the separated
serum collected. Insulin, adiponectin, and leptin analyses were per-
formed at the Core Biochemical Assay Laboratory (Cambridge, UK).
Glucose levels were determined using the Glucose Coulometric Assay
Kit (Cayman Chemical) and following the manufacturer’s protocol
provided. Serum triglyceride levels were determined using the Tri-
glyceride Liquid Assay (Sentinel Diagnostics) following the manufac-
turer’s instructions.
Quantitative insulin sensitivity check index (QUICKI) was calculated
from fasting glucose (mg/dL) and insulin (mU/mL) values as previouslyMOLECULAR METABOLISM- (2018) 1e11  2018 The Authors. Published by Elsevier GmbH. This is an
www.molecularmetabolism.comdescribed [32]. QUICKI ¼ 1/[log(I0) þ log(G0)], where I0 is fasting in-
sulin and G0 is fasting glucose. QUICKI is a dimensionless index
without units.
2.8. Liver TG assay
Frozen liver tissue samples were weighed and then homogenised in
1 ml of PBS. Samples were kept on ice at all times. Liver lysates were
centrifuged at 12,000g for 10 min at 4 C. The supernatant was
collected and triglyceride (TG) levels were determined using the Tri-
glyceride Liquid Assay (Sentinel Diagnostics) following the manufac-
turer’s instructions. TG levels were then normalised to individual tissue
weights.
2.9. Statistical analyses
All data are presented as the mean  SEM and were analysed by an
unpaired two-tailed Student’s t test or two-way analysis of variance
with Bonferroni post-hoc test as appropriate using GraphPad Prism.
Mendelian frequencies were analysed using a Chi-Square test. A P-
value <0.05 was considered as statistically significant.
3. RESULTS
3.1. Deletion of Bscl2 specifically in developing adipocytes is
sufficient to cause lipodystrophy
To investigate the consequences of disrupting Bscl2, we used a novel
mouse model generated from Bscl2tm1a(EUCOMM)Hmgu ES cells in which
exons 5e7 of the Bscl2 gene are flanked by LoxP sites (Figure 1A). To
validate this model, we first generated global seipin knockout (SKO)
mice. SKO mice did not display significant differences in body weight
(Figure 1B) but developed lipodystrophy (Figure 1C), glucose intoler-
ance (Figure 1D), and insulin insensitivity (Figure S1A), phenocopying
previously reported seipin knockout models [19e21]. Subsequently,
Bscl2-floxed mice were used to generate mice lacking seipin selec-
tively in developing and mature adipocytes (Ad-B2(/) mice) by
crossing with the adipose specific Adiponectin-Cre model [33]. Ad-
B2(/) mice were born at the expected Mendelian frequencies (HE/WT
23.6%, HE/HE 25.7%, HO/WT 30.4% and HO/HE 20.3%, n ¼ 237,
P ¼ 0.164). Similar to the SKO mice (Figure 1B), body weights and
gross morphology of Ad-B2(/) mice were not significantly different
from littermate controls (Ad-B2(þ/)) when fed a standard chow diet
(Figure 1E). The specificity of Bscl2 deletion was confirmed by qPCR,
which showed dramatically reduced mRNA levels in epididymal white
adipose tissue (EWAT) and brown adipose tissue (BAT) but not in liver,
kidney, heart (Figure 1F), or brain (data not shown). Western blot
analysis furthermore indicated that seipin protein levels were signifi-
cantly depleted in BAT of Ad-B2(/) mice (Figure 1G). Consistent with
a critical role for seipin in WAT development and/or maintenance
in vivo, Echo-MRI analysis revealed knockout mice had significantly
decreased fat mass levels at both six and twelve weeks of age
(Figure 2A) and only residual EWAT and subcutaneous WAT (SWAT)
remained (Figure 2B). H&E staining of sections from the residual EWAT
and SWAT indicated that Ad-B2(/) mice had a disorganised mixture
of hypertrophic and smaller adipocytes (Figure 2C). Gene expression
levels of Adipoq and Leptin were significantly reduced in EWAT of Ad-
B2(/) mice (Figure 2D) and serum analysis in fasted mice revealed
significantly decreased circulating adiponectin levels (Figure 2E),
although circulating leptin levels were not significantly reduced under
these conditions (Figure 2E & S1B). Despite a greater than 90%
decrease in Bscl2 mRNA and seipin protein expression (Figure 1FeG),
BAT in Ad-B2(/) mice showed only a modest reduction in total mass
(Figure 2F). However, H&E staining of sections from BAT revealedopen access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/). 3
Figure 1: Generation of Ad-B2(L/L) mice. (A) Targeting strategy for the conditional disruption of the Bscl2 gene. Body weights (B), dissection images with magnetic resonance
imaging (C), and glucose tolerance (D) of SKO mice (n ¼ 5e6). (E) Body weights and gross morphology of mice after Adiponectin-Cre recombination (n ¼ 7e8). (F) Bscl2 mRNA
levels of 16-week-old Ad-B2(þ/) and Ad-B2(/) mice in BAT, EWAT, liver, kidney, and heart (n ¼ 4e5). (G) Western blot analysis of Bscl2 protein from BAT of mice described in F
(n ¼ 4e5). All data are presented as the mean  SEM, *p < 0.05.
Original Articlealtered triglyceride accumulation in Ad-B2(/) mice, with numerous
large droplets rather than the normal multilocular morphology
observed in BAT of littermate controls (Figure 2G). Modest, significant
decreases in Pparg, Adipoq, and Cpt1b gene expression were found in
BAT, but no differences in Leptin, Ucp1 or Prdm16 were observed.
Interestingly, a w4 fold increase was observed in Pgc1a expression
(Figure 2H). Lean mass was significantly increased in Ad-B2(/) mice
at both 6 and 12 weeks of age (Figure 2I), a feature of congenital seipin
loss in mice [20]. In contrast, adipose-specific loss of seipin did not
lead to generalised organomegaly (Figure 2J), which is also typically
observed in seipin knockout mice, and kidney or heart weights were
not significantly different between genotypes (Figure S1C). The severe
hepatic steatosis seen in SKO mice (Figure 1C) and CGL2 patients [34]
was also not apparent in Ad-B2(/) mice (Figure 2J). Overall, these
findings reveal that loss of Bscl2 specifically in developing adipocytes
is sufficient to cause generalised lipodystrophy in early life in vivo,
leading to several, but not all, clinical features observed in CGL2 pa-
tients and global Bscl2 knockout mice.
3.2. Analysis of metabolic and mechanical adipose tissues in Ad-
B2(/) mice reveals depot-selective characteristics
CGL2 is notable for the loss of so-called “mechanical” adipose depots,
which are selectively retained in other forms of CGL. Hence, we next
determined the severity of adipose tissue loss due to Bscl2 ablation in
some less frequently examined metabolic and mechanical adipose
depots.
We first examined bone marrow adipose tissue (MAT), which has been
shown to be a highly metabolically active depot, capable of secreting
large quantities of adiponectin [35]. Osmium tetroxide staining of
whole tibiae from 16-week-old Ad-B2(/) mice (Figure 3A) and
quantification of MAT by mCT revealed severe depletion of total tibial4
 2018 The Authors. Published by Elsevier GMAT in Ad-B2(/) mice, resulting from loss of both constitutive MAT
(cMAT) of the distal tibia and regulated MAT (rMAT) in the mid-to-
proximal tibia (Figure 3B). We next examined the MAT located in the
caudal vertebrae of the tail, which has also been considered a region of
cMAT [36]. Surprisingly, adipocytes were readily apparent in this re-
gion (Figure 3C) and were not significantly different in terms of the
adipocyte area or adipocyte size distribution (Figure 3D). This suggests
that vertebral cMAT may be developmentally and/or functionally
distinct to cMAT in tibiae and other long bones.
To examine a depot classically thought of as “mechanical” adipose
tissue, we analysed the infrapatellar fat pad (IFP) from the knee joint
(Figure 3E). Although the size of the IFP was found to be not different
between genotypes (Figure 3F), there was a modest but significant
reduction in total number of IFP adipocytes in Ad-B2(/) mice
indicating a subtle disruption in this depot is apparent in this model
(Figure 3G). However, the IFP was largely spared, which was unex-
pected given the observed loss of mechanical adipose depots in CGL2
patients [34]. We examined whether the retention of IFP adipocytes in
Ad-B2(/) mice could result from less efficient targeting of this depot
by the Adiponectin-Cre model. Consistent with this, the expression of
Bscl2 mRNA was reduced by w60% in the IFP of Ad-B2(/) mice
(Figure 3H) compared with the 90% or greater reduction observed in
other adipose depots examined (Figure 1F). To determine whether
seipin was indeed needed for IFP development, we examined the IFP
in our SKO mice. This revealed that adipocytes of the IFP were almost
completely absent in these global seipin knockout mice (Figure 3I).
Taken together, our findings reveal that adipose-specific ablation of
Bscl2 using the Adiponectin-Cre line causes early-onset generalised
loss of adipose tissue but that a small number of specific depots,
such as the IFP, may be poorly targeted by the Adiponectin-Cre
model.MOLECULAR METABOLISM- (2018) 1e11
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Figure 2: Characterisation of Ad-B2(L/L) mice. (A) Fat mass normalised to body weight of Ad-B2(þ/) and Ad-B2(/) mice at 6 (n ¼ 4e7) and 12 weeks of age (n ¼ 7e8).
Dissection images (B) and representative 40 magnification images of H&E staining (C) of EWAT and SWAT sections of 12-week-old Ad-B2(þ/) and Ad-B2(/) mice. Relative
EWAT mRNA levels (D) and circulating serum levels (E) of adiponectin and leptin in 16-week-old Ad-B2(þ/) and Ad-B2(/) mice (n ¼ 4e5) fasted for 5 h. (F) Dissection image
and BAT weight normalised to body weight (n ¼ 4e5). (G) Representative 40 magnification images of H&E staining of BAT sections of 12-week-old Ad-B2(þ/) and Ad-B2(/)
mice. (H) mRNA levels of white and brown markers in BAT of 16-week-old Ad-B2(þ/) and Ad-B2(/) mice (n ¼ 4e5). (I) Lean mass at 6 (n ¼ 4e7) and 12 weeks of age
(n ¼ 7e8) normalised to body weight, and gross abdominal morphology (J) of 16-week-old Ad-B2(þ/) and Ad-B2(/) mice. All data are presented as the mean  SEM,
*p < 0.05.3.3. Severe metabolic dysfunction is not apparent in Ad-B2(/)
mice
To examine the metabolic consequences of adipose-specific ablation
of seipin, 14-week-old Ad-B2(/) mice were phenotyped in metabolic
cages. Food and water intake was not significantly different from
littermate controls (Figure S1D). Activity levels during the night were
also not altered; however, Ad-B2(/) mice were found to be signifi-
cantly less active during the day (Figure S1E). Energy expenditure
levels were not significantly altered between genotypes during either
day or night (Figure 4A); however, knockout mice had significantly
decreased respiratory exchange ratio (RER) values during the active
phase (Figure 4B), indicating an increased propensity towards lipid
oxidation. To further explore this, mice were challenged with a fast/re-
feed experiment and RER levels were continuously monitored. During aMOLECULAR METABOLISM- (2018) 1e11  2018 The Authors. Published by Elsevier GmbH. This is an
www.molecularmetabolism.com9-h fast, Ad-B2(/) mice had elevated starting RER values
compared to littermate controls (Figure 4C) and their mean RER levels
remained higher during much of the fasting period (Figure 4D). Upon
re-feeding, RER levels in both genotypes increased (Figure 4C),
however, Ad-B2(/) mice failed to increase their RER to the same
level as control mice, leading to significantly lower mean values
(Figure 4E). This is consistent with the data obtained during the active
phase in ad libitum fed mice (Figure 4B). Overall, these data indicate
that Ad-B2(/) mice may have a reduced flexibility to switch between
the use of lipids as fuel during fasting and carbohydrate upon
refeeding. To determine if this was detrimental to metabolic health, we
examined serum triglyceride, insulin, and glucose levels in 16-week-
old mice that had been fasted for a period of 5 h. No significant dif-
ferences were observed between control and Ad-B2(/) miceopen access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/). 5
Figure 3: Metabolic and mechanical adipose tissue in Ad-B2(L/L) mice. (A) Whole mouse tibiae stained with osmium tetroxide and (B) quantification of cMAT, rMAT, and total
MAT by mCT in 16-week-old Ad-B2(þ/) and Ad-B2(/) mice (n ¼ 4e5). Representative H&E staining of MAT from caudal vertebrae from the tail (C) and quantification of adipocyte
area and frequency of caudal vertebrae MAT (D) of mice described in A. (E) Representative H&E staining images of IFP sections in 12-week-old Ad-B2(þ/) and Ad-B2(/) mice. Scale
bar represents 100 mm. Quantification of IFP size (F) and adipocytes per section (G) of mice described in E (n ¼ 7). (H) Bscl2 mRNA levels of 12-week-old Ad-B2(þ/) and Ad-B2(/)
mice in IFP (n¼ 7). (I) Representative H&E staining images of IFP sections in WT and SKO mice. Scale bar represents 100 mm. All data are presented as the mean  SEM, *p< 0.05.
Original Article(Figure 4FeH) and quantitative insulin sensitivity check index (QUICKI)
analysis indicated that knockout mice were not insulin resistant
compared to littermate controls (Figure 4I). Ad-B2(/) mice did have
elevated liver triglyceride levels (Figure 4J and S1F), most likely due to
the absence of appropriate adipose tissue depots driving enhanced
hepatic lipid accumulation. However, the increase in liver TG levels in
Ad-B2(/) mice was much less severe than that seen in previously
reported Bscl2-null mice, consistent with the absence of overt liver
steatosis in our model (Figure 2J). Glucose tolerance tests (GTTs) were
performed to examine whether lipodystrophy and increased liver tri-
glycerides would cause glucose intolerance. At the start of the GTT, 5-
h fasted glucose levels were not significantly altered and, surprisingly,
Ad-B2(/) mice showed no impairment of glucose tolerance
(Figure 4K).
SKO mice have been reported to show induction of markers of ther-
mogenesis in residual EWAT deposits [20] and we next sought to
determine if this feature was shared in Ad-B2(/) mice. Although a
small but significant decrease in C/ebpa was apparent, no changes
were observed in the expression of other classical markers of WAT
including, Pparg, Glut4, Perilipin or aP2 (Figure 4L). We next examined6
 2018 The Authors. Published by Elsevier Gif the expression of markers characteristic of brite and brown adipo-
cytes [37] were altered. When brite adipocyte markers (Cd137, Cd40,
Tbx1, and Tmem26) were examined in Ad-B2(/) mice, only Cd137
was significantly elevated (Figure 4M). In contrast, expression of
almost all markers of brown adipocytes that were examined were
significantly increased, including Ucp1, Cpt1b, Pgc1a, Acot2, and
Pdk4, suggesting browning occurs the residual EWAT depot in Ad-
B2(/) mice (Figure 4N).
Overall, our data indicate that the loss of Bscl2 specifically in devel-
oping adipocytes causes lipodystrophy and ectopic lipid accumulation
in the liver, along with significantly altered substrate utilisation in
response to fasting and refeeding. However, this is not accompanied
by the overt metabolic dysfunction seen in global Bscl2 knockout mice.
3.4. High-fat-diet fed Ad-B2(/) mice resist weight gain and
remain glucose tolerant
In an effort to uncover any latent metabolic dysfunction, 8-week-old
Ad-B2(/) mice and littermate controls were challenged with a high-
fat diet (HFD, 60% kcal from fat) for four weeks. Ad-B2(/) mice
failed to gain as much weight as controls (Figure 5A). This wasMOLECULAR METABOLISM- (2018) 1e11
mbH. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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Figure 4: Physiological and metabolic phenotype of Ad-B2(L/L) mice. (A) Energy expenditure (EE) and (B) respiratory exchange ratio (RER) values in Ad-B2(þ/) and
Ad-B2(/) mice at 14 weeks of age fed a standard chow diet (n ¼ 4e5). (C) Mice as described in B were challenged with a 9-h fast and then given ad libitum access to chow diet
and RER values were collected throughout. Average RER values obtained during fasting (D) and re-feeding (E) periods (n ¼ 4e5). Analysis of serum triglyceride (F), insulin (G),
glucose (H), quantitative insulin sensitivity check index (QUICKI) analysis (I) and liver triglyceride levels (J) normalised to tissue weight in Ad-B2(þ/) and Ad-B2(/) mice fasted for
5 h at 16 weeks of age (n ¼ 4e5). (K) Glucose tolerance test in Ad-B2(þ/) and Ad-B2(/) mice at 10 weeks of age (n ¼ 4). Relative gene expression of white (L), brite (M) and
brown (N) adipocyte markers in EWAT of Ad-B2(þ/) and Ad-B2(/) mice at 16 weeks of age (n ¼ 4e5). All data are presented as the mean  SEM, *p < 0.05.significantly lower compared to control mice after 4 weeks on HFD,
when expressed as percentage of starting weight (Figure 5B). Echo-
MRI analysis again revealed Ad-B2(/) mice had significantly less fat
mass than littermate control mice prior to HFD feeding. Strikingly,
whilst adiposity more than doubled in control mice, Ad-B2(/) mice
were entirely unable to increase fat mass in response to HFD feeding
(Figure 5C). Lean mass, as a percentage of body mass, was signif-
icantly increased in Ad-B2(/) mice prior to HFD and remained
elevated during HFD feeding. In contrast, the percentage lean mass in
control mice steadily decreased when challenged with HFD as fat
mass increased (Figure 5D). To determine if the inability to store
triglycerides in adipose tissue was detrimental to metabolic health,
intraperitoneal GTTs were performed at various times during the HFD
challenge. In order to examine the acute effects of HFD, glucose
tolerance was first examined after 48 h of HFD feeding. Five-hour
fasted blood glucose levels were found to not be significantly
altered and disposal rates of the glucose bolus were not different
except at 60 min, when glycaemia in Ad-B2(/) mice was signifi-
cantly lower compared to control mice (Figure 3E). After two weeks of
HFD feeding, basal fasted glucose levels were again not significantly
different; however, Ad-B2(/) mice exhibited improved glycaemia atMOLECULAR METABOLISM- (2018) 1e11  2018 The Authors. Published by Elsevier GmbH. This is an
www.molecularmetabolism.comall time-points examined compared to control littermates (Figure 5F).
A final GTT was performed after four weeks of HFD to determine if
this effect persisted. Once again, fasting blood glucose levels were
found to be unaltered, while Ad-B2(/) mice displayed significantly
lower blood glucose levels after glucose bolus administration
compared to littermate controls (Figure 5G). Ad-B2(/) mice have a
greater percentage lean mass and in these experiments glucose
dosing was based on body weight. It is possible that the difference in
body composition may bias the GTT to suggest greater glucose
tolerance in the Ad-B2(/) mice than is the case. However, previous
studies of SKO mice have revealed marked glucose intolerance,
despite also dosing GTT glucose based on total body weight
[19,21]. Hence, whilst one should be cautious about concluding that
Ad-B2(/) mice are more glucose tolerant than control mice, they
are not glucose intolerant, like SKO mice.
When liver triglyceride levels were determined at the end of the HFD
period, no significant differences were observed between the geno-
types (Figure 5H). Comparison with absolute values for TG in chow fed
mice (Figure 4J) indicated that this resulted from increased liver TG
accumulation in control mice with HFD-feeding, whilst the elevated
liver TG levels in chow-fed Ad-B2(/) mice were not further increasedopen access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/). 7
Figure 5: Consequences of feeding Ad-B2(L/L) mice a high-fat diet. Body weight (A) and percentage body weight gain (B) in Ad-B2(þ/) and Ad-B2(/) mice fed a high-fat
diet (HFD) for four weeks, starting at 8 weeks of age (n ¼ 5e6). Fat mass (C) and lean mass (D) normalised to body weight at 0, 2 and 4 weeks of HFD feeding (n ¼ 5e6). Fasting
glucose levels and glucose tolerance tests performed after 48 h (E), 2 weeks (F), and 4 weeks (G) of HFD feeding (n ¼ 5e6). (H) Liver triglyceride levels normalised to tissue weight
following 4 weeks of HFD feeding (n ¼ 5e6). Relative gene expression of white (I), brite (J) and brown (K) adipocyte markers in EWAT of mice fed HFD for 4 weeks (n ¼ 5e6). All
data are presented as the mean  SEM, *p < 0.05.
Original Articlesubstantially by HFD. Lipid accumulation, visualised by oil red O
staining of liver sections from high-fat diet fed control and Ad-B2(/)
mice was consistent with assayed TG levels (Figure S1F).
Gene expression analysis of EWAT revealed either no change or
significantly decreased transcript levels of both white and brite-specific
markers in Ad-B2(/) mice compared to controls (Figure 5IeJ).
Conversely, numerous markers of browning (Ucp1, Cpt1b, Pgc1a,
P2rx5, Acot2, Pdk4, and Eva1) were all significantly elevated in
Ad-B2(/) mice (Figure 5K). Analysis of BAT revealed significant de-
creases in Pparg, Leptin, Adipoq, Ucp1, Cpt1b, and Prdm16 expression
implying that the failure of HFD to worsen the metabolic health of
Ad-B2(/) mice was unlikely to result from increased lipid oxidation in
BAT (Figure S1G). Overall, these results reveal that Ad-B2(/) mice are
unable to expand adipose tissue stores in response to a high-fat-diet
challenge. Despite this, the detrimental consequences commonly
associated with lipodystrophy in CGL2 are not observed.
4. DISCUSSION
The human lipodystrophy gene BSCL2 is known to be expressed in
numerous tissues throughout the body [3]. Investigating the conse-
quences of tissue-specific loss of seipin is therefore important to
further understand and characterise this condition. We find that loss of8
 2018 The Authors. Published by Elsevier Gseipin selectively in developing adipocytes in Ad-B2(/) mice leads to
several features seen in previously generated global Bscl2 knockout
mouse models including, critically, a severe lack of adipose tissue from
early in life [19e21]. Consistent with this, circulating levels of the
adipokine adiponectin were reduced. Moreover, Ad-B2(/) mice
challenged with a high-fat diet showed a striking failure to increase
their adipose mass, revealing an inability to increase triglyceride
storage or expand adipocyte number within their residual adipose
tissues. These findings provide the first in vivo confirmation that loss of
seipin specifically in developing adipocytes is sufficient to cause early-
onset generalised lipodystrophy. In addition, our data show that seipin
is important for adipose tissue expansion in adult mice, com-
plementing a previous study of inducible ablation of seipin in adipose
tissue in adults [27]. We observed significant alterations in fuel uti-
lisation in Ad-B2(/) mice as RER was higher than in controls during a
period of fasting but did not rise to the same extent as in controls
during re-feeding. We interpret this as an adaptation to an altered
availability of stored lipids during fasting due to the paucity of adipose
tissue, which may lead to a greater use of carbohydrate whilst glucose
remains available. Conversely, if dietary lipids cannot be appropriately
stored, they may make a greater contribution to fuel utilisation during
re-feeding in Ad-B2(/) mice, when control mice would instead
incorporate more lipids into adipose tissue and make greater use ofMOLECULAR METABOLISM- (2018) 1e11
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available carbohydrate. Future studies defining the mechanisms un-
derlying this effect may provide novel insights regarding the switching
between lipid and carbohydrate metabolism.
The phenotype we observe in Ad-B2(/) mice, using the Adiponectin-
Cre line, contrasts with a previous report using the aP2-Cre line to
knock out seipin, which concluded that seipin loss in adipocytes
resulted in a progressive lipodystrophy with apparently normal adipose
tissue development in early life [26]. This is likely to result from the
choice of Cre promoter used to ablate Bscl2 from adipocytes. Indeed,
our findings correlate with studies of adipose-selective ablation of
PPARg and the insulin receptor in which the use of Adiponectin-Cre
model has revealed an almost complete loss of adipose tissue
in vivo that is not evident using the aP2-Cre line [29,30,38,39]. Overall,
our work supports the findings of others that the Adiponectin-Cre line
is preferable for examining the in vivo effects of targeting genes
affecting adipose tissue development and function [24,25].
Intriguingly, we find that whilst the Adiponectin-Cre line clearly targets
all major white adipose depots, there may be some variation in tar-
geting efficiency between some of the less studied depots. Bone
marrow adipose tissue (MAT) is capable of secreting large quantities of
adiponectin [35]. Consistent with this, Bscl2 targeting in MAT of Ad-
B2(/) mice was highly efficient and led to severe depletion of both
cMAT and rMAT stores in the tibia. Ad-B2(/) mice therefore accu-
rately model CGL2 in this regard [34] and may be particularly valuable
for examining the consequences of severe MAT deficiency. However, it
is notable that cMAT in the tail vertebrae was intact in the Ad-B2(/)
mice. Further studies are required to determine either whether these
remaining adipocytes do not express adiponectin or if they do not
require seipin for their development or maintenance. Regardless of the
explanation for this, the selective maintenance of cMAT in the tail
vertebrae implies that there is a fundamental difference in the devel-
opment of axial vs appendicular MAT.
In contrast to tibial MAT but similar to vertebral MAT, we found that the
IFP in the knee joint was largely preserved in Ad-B2(/) mice. This
depot is almost completely ablated in global seipin knockout mice
(Figure 3H) and in CGL2 patients [40]. This strongly implies that the
Adiponectin-Cre poorly targets this depot, at least early in adipogenesis,
rather than that these adipocytes are unaffected by the absence of
seipin. Consistent with this, we observed a more modest reduction in
Bscl2 expression in the IFP, in contrast to other adipose tissues in
Ad-B2(/) mice which showed a near-complete ablation of Bscl2
expression. This adds to existing evidence that so-called “mechanical”
WAT depots may differ from other depots, including the observation that
this type of WAT is almost entirely absent in CGL2 patients but pre-
served in other forms of CGL [34,40]. This type of WAT remains poorly
understood but has been strongly implicated in joint disease [41]. Our
data suggest that targeting strategies other than the Adiponectin-Cre
model will be required to uncover its specific functions in vivo.
In addition to being lipodystrophic, Ad-B2(/) mice displayed signif-
icantly increased lean mass, a feature also seen in Bscl2 knockout
mice [20]. However, in contrast to global KO mice, Ad-B2(/) mice did
not exhibit generalised organomegaly, and kidney or heart weights
were not significantly altered. Hypertrophic cardiomyopathy and car-
diac dysfunction in Bscl2 knockout mice appears to be due to gluco-
toxicity [42]. The lack of an increase in heart mass in Ad-B2(/) mice
is consistent with this notion, as these mice are not hyperglycaemic or
hyperinsulinaemic. How adipose-specific seipin deficiency and/or lack
of adipose tissue drives increased lean mass remains an interesting
unanswered question.
We were surprised to find that, despite generalised lipodystrophy, Ad-
B2(/) mice did not develop glucose intolerance or insulinMOLECULAR METABOLISM- (2018) 1e11  2018 The Authors. Published by Elsevier GmbH. This is an
www.molecularmetabolism.comresistance, even when mice were challenged with a high-fat diet.
This finding is unexpected, as lipodystrophy resulting from adipose-
tissue-specific ablation of PPARg (PPARg-FKO) or the insulin receptor
(IR-FKO) using the Adiponectin-Cre line both result in severe meta-
bolic dysfunction [29,30]. Due to the critical role of PPARg in brown
adipogenesis, PPARg-FKO mice lack BAT, whist in IR-FKO mice, BAT
and any residual WAT will be insensitive to insulin. Previous studies
have reported that Bscl2 is not required for brown adipocyte differ-
entiation or development [43,44]. Consistent with this, Ad-B2(/)
mice developed interscapular BAT, albeit with modestly reduced
mass, altered gene expression and lipid droplet morphology. More-
over, seipin-deficient brown adipocytes are not inherently insulin
resistant, although they may become so indirectly in global seipin
knockout mice [44]. Hence, preservation of BAT, and insulin sensi-
tivity in BAT and residual WAT, may at least partly explain why Ad-
B2(/) mice do not develop the overt metabolic disease seen in
PPARg-FKO and IR-FKO mice.
In contrast, preserved BAT function and insulin sensitivity are unlikely
to explain why Ad-B2(/) mice are glucose tolerant whilst global
Bscl2 knockout mice are not. Both BAT development and browning of
residual EWAT are also evident in Bscl2 knockout mice but do not
prevent overt metabolic disease, suggesting that other mechanisms
must underlie this difference [19e21]. Also, the absolute mass of
these residual EWAT depots is very small. Nonetheless, the browning
of residual EWAT in all these seipin-deficient models is intriguing and
might arise from the presence of bipotential precursor cells with the
capacity to form BAT or WAT, which are forced by seipin deficiency
towards brown adipogenesis. Given the array of distinct stem cells with
adipogenic potential that have been reported, future lineage tracing
studies may offer valuable insights regarding the nature of the adi-
pocytes in these residual EWAT depots [45].
The restoration of Bscl2 expression selectively in adipocytes of Bscl2
knockout mice not only prevents lipodystrophy, but also insulin
resistance and hepatic steatosis [23]. Although this indicates that
these features of CGL2 are a consequence of the absence of appro-
priate adipose lipid storage capacity, they do not specifically address
whether loss of seipin in non-adipose tissues may worsen metabolic
health when adipose tissue is dysfunctional or absent. Our data raise
the possibility that adipose tissue-specific ablation of Bscl2 alone may
be insufficient to cause all features of the severe metabolic disease
observed in congenital seipin deficiency, at least in mice. One notable
finding is that Ad-B2(/) mice fail to develop severe hepatomegaly.
Although liver triglycerides were elevated in chow-fed Ad-B2(/)
mice, overt hepatic steatosis was not observed and this was not
exacerbated with high-fat diet feeding. Bscl2 ablation specifically in
the liver does not appear to lead to hepatic steatosis or diabetes, even
when the mice are challenged with a high-fat diet [46]. However,
adipose tissue mass was normal in these mice and may protect
against the loss of Bscl2 in the liver by safely storing additional fat and
preventing ectopic hepatic triglyceride accumulation. A recent study
has shown that seipin could play an important role in lipid storage
within hepatocytes and that decreasing seipin expression in either
primary or cultured hepatocytes increased the number and size of lipid
droplets in these cells [47]. This appeared to be driven by greater fatty
acid uptake and de novo lipogenesis. If seipin does have a cell-
autonomous role regulating lipid handling within hepatocytes, this
could explain the discrepancy in hepatic steatosis between Ad-B2(/)
and global Bscl2 knockout mice. Hence, it remains plausible that seipin
loss in hepatocytes, when adipose stores are also absent, could alter
lipid homoeostasis and the regulation of gluconeogenesis, contributing
to hyperglycaemia.open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/). 9
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mass is greater in Ad-B2(/) mice than in SKO mice, even if these
remain quantitatively very small. This may still provide enough adipose
storage capacity or adipokine secretion to protect the Ad-B2(/) mice
from metabolic disease. Further studies of ablation of seipin in non-
adipose tissues of Ad-B2(/) mice or additional ablation of me-
chanical adipose depots in these mice will be needed to determine
whether this is the case.
In conclusion, we have generated a novel mouse model of adipose-
specific Bscl2 disruption. This reveals that the loss of seipin in
developing adipocytes is sufficient to cause the early-onset general-
ised lipodystrophy observed in CGL2 patients with mutations in BSCL2.
Moreover, substrate utilisation is significantly altered, demonstrating
that the lack of adipose tissue drives metabolic adaptation in these
mice. However, we do not observe the full phenotype of metabolic
disease, particularly the severe hepatic steatosis, glucose intolerance
and insulin resistance observed with congenital seipin deficiency in
both humans and mice. This implies that there could be additional
metabolically relevant roles for seipin in other tissues, and/or that
recovery of quantitatively very modest adipose depots may be suffi-
cient to alleviate metabolic disease in this rare but devastating
condition.
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